Psychiatric Hair Loss Treatment

Hair loss treatment as psychiatric medicine

Hair loss can directly worsen body image distress, depressive symptoms, social avoidance, and treatment engagement. At Welmivia, addressing it is part of psychiatric care — not a cosmetic detour.

Schedule a Fit Call
FDA-Approved Focus
Finasteride, minoxidil, spironolactone, plus evidence-based psychiatric integration.
Integrated Care
Treatment decisions are made in the context of mood, anxiety, stress, and medication effects.
Evidence-Based
Includes pathways for androgenic loss, stress shedding, medication-related loss, and trichotillomania.
The Clinical Case

Hair loss and psychiatric illness are bidirectionally linked

The relationship runs both directions. Psychiatric illness causes hair loss. Hair loss compounds psychiatric illness. Neither can be addressed in isolation.

Chronic stress and HPA axis dysregulation drive telogen effluvium. Psychiatric medications — valproate, lithium, SSRIs, and antipsychotics — can cause or accelerate hair loss. Androgenic hair loss can intensify body image distress and depressive symptoms. Trichotillomania is itself a primary psychiatric disorder.

Every hair loss intervention at Welmivia requires a documented psychiatric indication and a clinical narrative connecting the hair loss to the psychiatric presentation. This is not cosmetic medicine.

“We are treating your hair loss because of its direct impact on your mental health. The visible results are a psychiatric outcome.”
Patient education standard at Welmivia
Referral scope boundary
Scarring alopecias, severe refractory alopecia areata requiring JAK inhibitors, and procedural interventions such as PRP or hair transplant are outside Welmivia prescribing scope. Dermatology referral is initiated when indicated.
Clinical Decision Framework

Hair loss type determines treatment pathway

Male AGA
Androgenic Alopecia — Male Pattern
DHT-mediated follicle miniaturization
Anti-androgens plus minoxidil, with targeted hormonal review when indicated.
Female AGA
Androgenic Alopecia — Female Pattern
Androgen sensitivity plus hormonal shifts
Full hormonal evaluation, spironolactone or minoxidil when appropriate, and root-cause assessment.
Telogen — Stress
Stress-Induced Telogen Effluvium
HPA axis disruption and diffuse shedding
Treat the psychiatric driver, support recovery, and consider minoxidil and nutritional optimization.
Telogen — Medication
Medication-Induced Hair Loss
Direct drug effect on follicle cycling
Review medication timeline, decide whether to continue, and use supportive treatment when needed.
Trichotillomania
Trichotillomania (F63.3)
Psychiatric and OCD-spectrum
Primary treatment is psychiatric: NAC, SSRI optimization, and behavioral therapy referral.
Hormonal
Perimenopausal & Postpartum
Hormonal withdrawal patterns
Assess hormonal contribution directly and use hair-specific treatment as an adjunct when needed.
Evidence-Based Agents

FDA-approved medications and robust clinical evidence

Finasteride
FDA Approved
Oral 1 mg · or topical compounded
Reduces scalp DHT and helps halt progressive follicular miniaturization. Used for pattern hair loss when the androgenic mechanism is clinically supported.
Dutasteride
Off-Label (US)
Oral 0.5 mg · or topical compounded
Considered for more aggressive androgenic loss or when response to finasteride is inadequate.
Spironolactone
Women Only
Oral 25–200 mg
Appropriate for selected women with androgen-related hair loss. Requires contraception counseling when relevant, renal and potassium monitoring, and extra caution with lithium.
Minoxidil
FDA Approved (Topical)
Topical · or oral low-dose
A broad follicular support option across multiple hair loss types. Patients should be told that early shedding can happen before improvement becomes visible.
Medication-Induced Alopecia

Psychiatric medications that can contribute to hair loss

Mood Stabilizers
Valproate and lithium can be associated with medication-related shedding. The timeline, severity, and other reversible contributors should be reviewed carefully.
Antidepressants
SSRIs can contribute to telogen effluvium in some patients. Welmivia’s approach is to document the time relationship, weigh psychiatric benefit against burden, and support the patient through the shedding window when appropriate.
Antipsychotics
Antipsychotics may contribute directly or indirectly, including through prolactin-related pathways in selected cases.
Hormonal Contraceptive Contributors
In susceptible patients, androgenic progestin exposure can worsen pattern hair loss and should be reviewed in the broader hormonal picture.
Ferritin — commonly missed
Standard ferritin reference ranges are built for anemia detection, not hair optimization. A ferritin level that appears “normal” on a routine lab panel may still be relevant in diffuse shedding, so this is reviewed early in the evaluation.
Questions

What patients ask us

My antidepressant caused my hair to fall out. Can Welmivia help?
Yes. The timeline, severity, and necessity of continuing the medication are reviewed, and supportive treatment may be used while monitoring the psychiatric picture.
I have trichotillomania. Is that something Welmivia treats?
Yes. Trichotillomania is treated as a primary psychiatric condition, with NAC, SSRI optimization when appropriate, and referral for therapy with BFRB or CBT experience.
I’ve been told my ferritin is normal. Why is Welmivia concerned about it?
Because hair-relevant ferritin targets can differ from the thresholds used to flag anemia on standard lab reports.
I’m on lithium. Can I take spironolactone for female hair loss?
This requires caution and monitoring, because spironolactone can affect lithium handling and raise toxicity concerns.

Ready to evaluate hair health within the bigger picture?

New patients begin with a Precision Psychiatric Evaluation to assess contributing factors, treatment history, medication context, and whether hair-focused interventions fit appropriately within your overall care plan.

Ready to schedule?

Start with a Precision Psychiatric Evaluation

Interested in integrated GLP-1, hormone, peptide, hair, or sexual wellness support? New patients begin with a comprehensive Precision Psychiatric Evaluation to clarify goals, review history, and determine whether these services fit appropriately within your care plan.

Initial evaluation: $450
Virginia & Florida residents only
Direct-pay · Superbills on request

Ongoing monitored adjunctive therapies, including GLP-1 and peptide-based metabolic management, are addressed within the Welmivia care framework after evaluation when clinically appropriate.

Get in touch

Contact Welmivia

Questions about services, scheduling, or what to expect? We respond within one business day.

admin@welmivia.com (434) 623-0003

Existing patients: log into the patient portal for clinical messages.

Message received

Thank you for reaching out. We'll be in touch within one business day.

For general inquiries only. Not for urgent medical concerns.